TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›TIL›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Instil Bio, Inc. (TIL) financials

Income statement

Instil Bio, Inc. (TIL) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue$138K$0.00————
Revenue growth—-100.0%————
Operating income-$33.6M-$156M-$226M-$159M-$73.5M-$78.6M
Operating margin-24379.7%—————
Net income-$37.7M-$157M-$223M-$156M-$74.1M-$71.4M
Net margin-27346.4%—————
EPS (diluted)-$2.36-$1.48-$34.46-$24.00-$11.39-$10.70

Cash flow

Instil Bio, Inc. (TIL) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$29.6M-$122M-$180M-$82.0M-$55.7M-$36.6M
Capital expenditures$50.8M$57.8M$84.6M$20.7M$0.00—
Free cash flow-$80.4M-$180M-$265M-$103M-$55.7M—

Balance sheet

Instil Bio, Inc. (TIL) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$242M$37.6M$43.7M$9.20M$8.80M$6.64M
Total assets$319M$610M$482M$326M$264M$204M
Total liabilities$26.6M$54.8M$119M$99.8M$94.1M$89.7M
Shareholders' equity-$39.6M$555M$364M$226M$169M$114M
Retained earnings-$44.9M-$202M-$425M-$581M-$655M-$726M
Shares (wtd avg diluted)16.0M106M6.48M6.50M6.51M6.67M

Every figure is extracted from Instil Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does TIL pay a dividend?
Instil Bio, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full TIL analysis — verdict, score & filings →Is TIL a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.